Mesoblast
MESO
10.89
-0.29
-2.59%
Mesoblast
US · MESO
#2849 by market cap
Listed 2015
10.89
-0.29
-2.59%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 5 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.5 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 28.80% -0.49pp
- Institutions
- 110 -5
- As of
- 2026/Q3 vs. prior period
Holder types
Individual/Insider34.17%
Mutual Fund17.73%
Public Company6.44%
Private Company1.70%
VC/PE Fund1.08%
Government Pension Fund0.88%
Sovereign Wealth Fund0.85%
Other37.02%
Top holders as of 2026-09-18
Gregory George
20.95% · 27.20M sh
Silviu Itescu
6.23% · 8.08M sh
State Street Global Advisors
5.16% · 6.70M sh
William Gueck
4.80% · 6.24M sh
JPMorgan Chase & Co.
4.65% · 6.04M sh
M&G Investment Management Limited
2.73% · 3.55M sh
Vanguard Capital Management, LLC
2.47% · 3.21M sh
BlackRock
1.87% · 2.43M sh
Vanguard Investments Australia Limited
1.57% · 2.04M sh
Dimensional Fund Advisors
1.36% · 1.76M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
25 filings tracked · 1 buys · 0 sells
| Name | Role | Stake |
|---|---|---|
| Gregory George | Non-Independent Non-Executive Director | 20.95% |
| Silviu Itescu | Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director | 6.23% |
| Eric Rose | Chief Medical Officer | 0.52% |
| Jane Bell | Independent Non-Executive Director | 0.05% |
| Philip Krause | Former Non-Independent Non Executive Director | 0.02% |
| William Burns | Former Independent Non-Executive Vice Chairman | 0.02% |
| Lynette Cobley | Independent Non-Executive Director | 0.00% |
| Philip Facchina | Independent Non-Executive Chair of the Board | 0.00% |
| Josaka Investments Pty Ltd. | -- | -- |
| James O’Brien | Chief Financial Officer | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-03-17 | Eric Rose | Chief Medical Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Philip Facchina | Independent Non-Executive Chair of the Board | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | William Burns | Former Independent Non-Executive Vice Chairman | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Silviu Itescu | Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Lynette Cobley | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Josaka Investments Pty Ltd. | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Jane Bell | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Philip Krause | Former Non-Independent Non Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Gregory George | Non-Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-15 | Gregory George | Non-Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2025-12-22 | James O’Brien | Chief Financial Officer | Other Derivative Acquisition | +650,000 | $2.90 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Mesoblast discussion 0 comments